Company: CSTL
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0001628280-25-048254
Chunk: 147

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-11-03
Form: 10-Q
Item: Item 8
Chunk 147
---
 periods indicated (in thousands, except percentages):

 Three Months EndedSeptember 30,Change 20252024(unaudited)NET REVENUES$83,043 $85,782 $(2,739)(3.2)%OPERATING EXPENSESCost of sales (exclusive of amortization of acquired intangible assets)18,704 15,609 3,095 19.8 %Research and development12,960 12,323 637 5.2 %Selling, general and administrative55,907 50,499 5,408 10.7 %Amortization of acquired intangible assets2,276 2,272 4 0.2 %Total operating expenses, net89,847 80,703 9,144 11.3 %Operating (loss) income(6,804)5,079 (11,883)(234.0)%Interest income2,833 3,404 (571)(16.8)%Changes in fair value of equity securities3,561 — 3,561 NAInterest expense(24)(201)177 88.1 %Other expense48 — 48 NA(Loss) income before income taxes(386)8,282 (8,668)(104.7)%Income tax expense115 6,013 (5,898)(98.1)%Net (loss) income$(501)$2,269 $(2,770)(122.1)%

NA = Not applicable

The following table indicates the amount of stock-based compensation expense (non-cash) reflected in the line items above (in thousands):

Three Months EndedSeptember 30,20252024Change(unaudited)Cost of sales (exclusive of amortization of acquired intangible assets)$1,446 $1,464 $(18)Research and development1,950 2,345 (395)Selling, general and administrative8,704 9,218 (514)Total stock-based compensation expense$12,100 $13,027 $(927)

The following table provides a disaggregation of net revenues by type (in thousands):

Three Months EndedSeptember 30,20252024Change(unaudited)Dermatologic(1)$48,523 $65,060 $(16,537)Non-Dermatologic(2)34,520 20,722 13,798 Total net revenues$83